Related Experiment Video
Updated: Jan 20, 2026

An In Vitro Organ Culture Model of the Murine Intervertebral Disc
Published on: April 11, 2017
Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt
Agila Kumari Pragasam1, Balaji Veeraraghavan1, Baby Abirami Shankar1
1Department of Clinical Microbiology, Christian Medical College, Vellore, Tamil Nadu, India.
Introduction:
Carbapenem resistance (CR) in Klebsiella pneumoniae is mainly mediated by bla NDM and bla OXA-48 carbapenemases. Newer Food and Drug Administration-approved antimicrobial ceftazidime/avibactam (C/A) has a potent activity against bla OXA-48-like producers. However, its activity is limited in organisms co-producing bla NDM and bla OXA-48-like. Addition of aztreonam (ATM) to C/A potentially expands the spectrum of coverage for carbapenemase co-producers. With this, we aimed to determine the synergistic activity of combination of C/A plus ATM against bla NDM, bla OXA-48-like and co-producers of bla NDM + bla OXA-48-like producing CR Klebsiella pneumoniae (CRKp).
Materials And Methods:
A total of 12 isolates of CRKp-harbouring genes encoding bla NDM and bla OXA-48-like were tested. Minimum inhibitory concentrations (MICs) were determined for several antimicrobial agents, including C/A (0.5-8 μg/ml) by broth microdilution method. Checkerboard assay was performed for the combination of C/A plus ATM at varying concentrations. Fold differences in the MIC of C/A with and without addition of ATM were determined to infer synergistic effects.
Results:
MIC of C/A and ATM ranged from 0.5 to >8 μg/ml and 64 to 2048 μg/ml, respectively. Two isolates were susceptible to C/A with MIC of 0.5 and 1 μg/ml, while others were resistant with MIC of >8 μg/ml. Synergistic effects of >8-fold MIC difference in C/A MIC were noted with addition of ATM at 4 μg/ml. This was observed for all CRKp with profiles of bla NDM, bla OXA-48-like and co-producers of bla NDM + bla OXA-48-like genes, which was a promising effect. Notably, all five of the colistin-resistant CRKp were inhibited with >8-fold MIC difference in the combination of C/A plus ATM at 4 μg/ml.
Conclusion:
With the increasing burden of CRKp, the use of C/A with ATM combination seems to be very promising, especially for bla NDM, bla OXA-48-like and co-producers of bla NDM + bla OXA-48like carbapenemases.
Insights
The combination of ceftazidime/avibactam (C/A) plus aztreonam (ATM) shows synergistic activity against carbapenem-resistant Klebsiella pneumoniae (CRKp) producing NDM and OXA-48 carbapenemases. This combination therapy is promising for treating difficult-to-treat CRKp infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Antimicrobial Resistance
Background:
- Carbapenem resistance (CR) in Klebsiella pneumoniae is a growing global health threat, primarily driven by carbapenemases like NDM and OXA-48.
- Ceftazidime/avibactam (C/A) is effective against OXA-48-like carbapenemase producers but less so against NDM co-producers.
- Aztreonam (ATM) addition to C/A may broaden its activity against carbapenemase co-producers.
Purpose of the Study:
- To evaluate the synergistic antimicrobial activity of ceftazidime/avibactam (C/A) in combination with aztreonam (ATM).
- To assess this combination against Klebsiella pneumoniae isolates harboring bla NDM, bla OXA-48-like, or both carbapenemase genes.
Main Methods:
- Minimum inhibitory concentrations (MICs) of C/A and ATM were determined for 12 carbapenem-resistant Klebsiella pneumoniae (CRKp) isolates.
- A checkerboard assay was employed to evaluate the synergistic effects of the C/A plus ATM combination.
- Fold differences in C/A MIC with and without ATM were calculated to infer synergy.
Main Results:
- Ceftazidime/avibactam (C/A) monotherapy showed high MICs (>8 μg/ml) for most CRKp isolates.
- Addition of aztreonam (ATM) at 4 μg/ml resulted in a >8-fold reduction in C/A MIC across all tested CRKp, indicating synergistic activity.
- This synergistic effect was observed for isolates with bla NDM, bla OXA-48-like, and co-producing bla NDM + bla OXA-48-like genes, including colistin-resistant strains.
Conclusions:
- The combination of ceftazidime/avibactam (C/A) plus aztreonam (ATM) demonstrates significant synergistic activity against carbapenem-resistant Klebsiella pneumoniae (CRKp).
- This combination is a promising therapeutic strategy for CRKp infections mediated by NDM, OXA-48-like, and co-producing carbapenemases.
- The findings support the potential clinical utility of C/A plus ATM for challenging CRKp infections.
Related Concept Videos
Transgenic Organisms
Accessory Organs
Methods for Studying Drug Absorption: In vitro
The diffusion cell method uses a two-compartment cell, including a donor compartment with the drug solution, which simulates the environment where the drug is applied, and a receptor compartment with a buffer solution, which simulates the environment...
Types of Genetic Transfer Between Organisms
Levels of Organization
Molecules Are Composed of Atoms, and Biomolecules Are Assembled from Molecules:
The most basic levels include atoms, molecules, and biomolecules. Atoms, the smallest unit of ordinary matter, are composed of a nucleus and electrons. Molecules...
Organic Compounds

